Servier To Acquire a Potential Best-in-Class Precision Therapy for Acute Leukemias, from BioNova Pharmaceuticals
All the news from Servier Group
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
Servier announces the appointment of Nitza Thomasson as Executive Director R&D Neurology
Tackling Inequities in Childhood Cancer Through Unique Global Collaboration
Servier delivers strong results in 2023/2024 and outpaces its trajectory to 2030
Servier appoints David K. Lee to Executive Committee
Servier inaugurates a bioproduction plant in France to support the growth of its R&D programs
Servier steps up commitment to digital innovation for patients with Klineo partnership
Servier Executive Committee appointments